Coversin topical (nomacopan topical) / Akari Therap - LARVOL DELTA

Comparison of topical Nomacopan, a dual Complement and leukotriene LTB4 inhibitor, with dexamethasone in downregulating experimental allergic conjunctival disease (EAC) (ARVO 2022) - "Topical Nomacopan suppressed inflammation in EAC by downregulating Th2 and Th9 cells, whereas dexamethasone only decreased Th9 cells, suggesting Nomacopan as an additional treatment option for allergic eye disease. 1Eskandarpour ME et al. Allergy."

Ophthalmology • CD4 • GATA3 • IL4 • IL9

Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results. (PubMed, Orphanet J Rare Dis) - "In this open label phase 1 TRACKER trial, rVA576 eye drops were well tolerated and showed a response across signs and symptoms of active inflammation. This study is exploratory but supports topical rVA576 safety and shows promising efficacy for recalcitrant AKC. A phase 2 randomised control trial is currently underway."

Clinical • Journal • P1 data • Conjunctivitis • Dry Eye Disease • Immunology • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis (clinicaltrials.gov) - P1/2; N=12; Terminated; Sponsor: AKARI Therapeutics; N=19 ➔ 12; Active, not recruiting ➔ Terminated; The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576/Coversin.

Clinical • Enrollment change • Trial termination • Conjunctivitis • Dry Eye Disease • Ocular Inflammation • Ophthalmology